Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18


52102 items
12:00 AM, Apr 25, 2000  |  BC Extra | Company News

BLA delay for Xoma and Baxter

The FDA told XOMA and partner BAX that data from their Phase III trial of Neuprex to treat meningococcemia were not sufficient to support the filing of a BLA. The FDA's decision comes as no...
12:00 AM, Apr 25, 2000  |  BC Extra | Company News

Amersham to distribute Vitex's Inactine

Amersham Pharmacia Biotech (Uppsala, Sweden) acquired exclusive global distribution rights to VITX's Inactine technology to inactivate viruses in blood, plasma and biopharmaceutical products....
12:00 AM, Apr 25, 2000  |  BC Extra | Company News

InphoGene to use Affymetrix chips

InphoGene BioCom (Vancouver, B.C.) will use AFFX's GeneChip with its tissue samples to build an online database of gene expression data associated with cardiopulmonary disease. InphoGene will pay AFFX subscription fees and royalties....
12:00 AM, Apr 25, 2000  |  BC Extra | Top Story

SmithKline returns rights to Coulter

SmithKline Beecham (LSE:SB; SBH) returned development and commercialization rights to CLTR's Bexxar cancer therapy outside the U.S. As a result, CLTR will be eligible for less than the $76 million in milestones possible under the...
12:00 AM, Apr 25, 2000  |  BC Extra | Company News

Digital Gene licenses TOGA to Mayo

The Mayo Foundation for Medical Education and Research will use the TOGA total gene expression analysis technology developed by Digital Gene (La Jolla, Calif.) to identify target genes involved in breast and ovarian cancer. Mayo...
12:00 AM, Apr 25, 2000  |  BC Extra | Company News

Visible Genetics licensing deal with PEB

The companies settled patent infringement litigation through a global licensing agreement that gives VGIN access to PE Biosystems (PEB) technology to manufacture and sell DNA sequencing instruments and clinical sequencing kits. VGIN will pay PEB...
12:00 AM, Apr 25, 2000  |  BC Extra | Financial News

Delsys raises $26 million

Drug delivery company Delsys (Princeton, N.J.) raised $26 million in a venture round. Investors included International Biotechnology Trust; STAR Ventures; HealthCare Ventures; Rho Management; Hudson Trust; CenterPoint Ventures; Prism Venture Partners; and Johnson & Johnson...
12:00 AM, Apr 25, 2000  |  BC Extra | Financial News

Amgen meets Street EPS

AMGN reported first quarter EPS of $0.25 after the market close on Tuesday, in line with the Street consensus. Going forward, the company raised its guidance on the year to $1.06-$1.08 from $1.05-$1.07. Sales of...
12:00 AM, Apr 25, 2000  |  BC Extra | Clinical News

Centaur completes CPI-1189 enrollment

Centaur (Sunnyvale, Calif.) completed enrollment of 64 HIV patients with cognitive and motor impairment in a placebo-controlled Phase IIa study of CPI-1189 nitrone-related therapeutic to treat AIDS dementia complex. The company said the compound functions...
12:00 AM, Apr 24, 2000  |  BC Extra | Financial News

NeoRx raises $19 million

NERX, which is developing cancer treatments, raised $19 million through the sale of 1.7 million shares at $11. Adams, Harkness & Hill; and Roth Capital Partners served as placement agents. NERX was down $0.75 to...